Results 101 to 110 of about 4,490 (182)

Identifying Antibiotic Effects of Investigational Drugs on Commensal Bacteria with Machine Learning. [PDF]

ACS Pharmacol Transl Sci
Gowda H, Lu W, Skaluba P, Xiang Y, McCann JR, McCoubrey LE, Rawls JF, Venturelli OS, Reker D.   +8 more
europepmc   +1 more source

ETV6-NTRK3 Fusion-Positive Late-Recurrent Parotid Carcinoma With Contralateral Axillary Metastasis and Early Response to Entrectinib: A Case Report. [PDF]

Cureus
Manea CA, Grigorean V, Serban D, Smarandache CG, Badiu DC.   +4 more
europepmc   +1 more source

Association of PD-L1 expression and clinical outcomes in ROS1-rearranged advanced non-small cell lung cancer treated with entrectinib. [PDF]

Transl Lung Cancer Res
Chen L, Shi W, Cao Z, Lu L, Wang A, Sun J, Ouyang Y, Xu P, Tang J, Li Z.   +9 more
europepmc   +1 more source

From waste to wealth: upcycling tilia tea waste into fluorescent N,S-CQDs for the determination of entrectinib in environmental water. [PDF]

RSC Adv
El-Deen AK, Radwan AS, Magdy G, Hashem HM, Belal F, Elmansi H.   +5 more
europepmc   +1 more source

Zidesamtinib (Jideytro®): a new selective, brain-penetrant ROS1 inhibitor approved for the treatment of ROS1-positive non-small cell lung cancer. [PDF]

Med Chem Res
Lee S, Hu L.
europepmc   +1 more source

Case Report: Dynamic TKI combination strategies for EGFR-mutant NSCLC with acquired ROS1 fusion and brain metastases. [PDF]

Front Oncol
Yang H, Da Y, Shen G, Sun QY, Yao ZY, Zhou YJ.   +5 more
europepmc   +1 more source

Intracranial Efficacy of Crizotinib and Postprogression Therapeutic Strategies in Advanced c-ros Oncogene 1 (ROS1)-Positive Non-Small Cell Lung Cancer (NSCLC), a Multicenter Real-World Study. [PDF]

MedComm (2020)
Zou Z, Zheng X, Tian P, Liu Z, Hu J, Fang Y, Xia Y, Ye F, Lv T, Li L, Zhong D, Zhou J, Chu Q, Shi M, Han C, Cao B, Huang D, Guo H, Lin G.   +18 more
europepmc   +1 more source

Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial

Although comprehensive biomarker testing is recommended for all patients with advanced/metastatic non-small cell lung cancer (NSCLC) before initiation of first-line treatment, tissue availability can limit testing.
Assaf, Zoe June, Nadal, Ernest, Cadranel, Jacques, Diarra, Cheick, Shagan, Sarah M, Mathisen, Michael, Moskovitz, Mor, Tanaka, Tomohiro, Mok, Tony, Peters, Solange, Sugawara, Shunichi, Swalduz, Aurélie, Archer, Venice, Dziadziuszko, Rafal, Maclennan, Margaret, Chiu, Chao-Hua, Bhagawati-Prasad, Vijay, Kilickap, Saadettin, Gadgeel, Shirish M, Yu, Chong-Jen, Nersesian, Rhea   +20 more
core   +1 more source

Entrectinib-Induced Sinus Bradycardia in a Patient With Metastatic Non-Small Cell Lung Cancer. [PDF]

JACC Case Rep
Talasaz AH, Goldberg AJ, Shu CA, Sayer GT, Uriel N, Raikhelkar JK.   +5 more
europepmc   +1 more source

Entrectinib attenuates LPS-induced neuroinflammation by inhibiting JNK, p38, and AKT pathways and ameliorates cognitive impairment. [PDF]

Arch Pharm Res
Woo H, Kim SW, Kim S, Chae S, Kim J.
europepmc   +1 more source